1. Home
  2. NAMS vs USAC Comparison

NAMS vs USAC Comparison

Compare NAMS & USAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • USAC
  • Stock Information
  • Founded
  • NAMS 2019
  • USAC 1998
  • Country
  • NAMS Netherlands
  • USAC United States
  • Employees
  • NAMS N/A
  • USAC N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • USAC Natural Gas Distribution
  • Sector
  • NAMS Health Care
  • USAC Utilities
  • Exchange
  • NAMS Nasdaq
  • USAC Nasdaq
  • Market Cap
  • NAMS 2.7B
  • USAC 3.0B
  • IPO Year
  • NAMS N/A
  • USAC N/A
  • Fundamental
  • Price
  • NAMS $26.73
  • USAC $24.32
  • Analyst Decision
  • NAMS Strong Buy
  • USAC Hold
  • Analyst Count
  • NAMS 10
  • USAC 4
  • Target Price
  • NAMS $41.40
  • USAC $25.50
  • AVG Volume (30 Days)
  • NAMS 984.0K
  • USAC 222.6K
  • Earning Date
  • NAMS 11-05-2025
  • USAC 11-04-2025
  • Dividend Yield
  • NAMS N/A
  • USAC 8.58%
  • EPS Growth
  • NAMS N/A
  • USAC 24.37
  • EPS
  • NAMS N/A
  • USAC 0.66
  • Revenue
  • NAMS $64,006,000.00
  • USAC $981,219,000.00
  • Revenue This Year
  • NAMS N/A
  • USAC $7.21
  • Revenue Next Year
  • NAMS $1.67
  • USAC $4.61
  • P/E Ratio
  • NAMS N/A
  • USAC $36.86
  • Revenue Growth
  • NAMS 762.15
  • USAC 8.22
  • 52 Week Low
  • NAMS $14.06
  • USAC $21.24
  • 52 Week High
  • NAMS $27.35
  • USAC $30.10
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 59.23
  • USAC 55.81
  • Support Level
  • NAMS $23.05
  • USAC $23.91
  • Resistance Level
  • NAMS $27.35
  • USAC $24.68
  • Average True Range (ATR)
  • NAMS 1.52
  • USAC 0.57
  • MACD
  • NAMS -0.11
  • USAC 0.10
  • Stochastic Oscillator
  • NAMS 85.58
  • USAC 79.07

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About USAC USA Compression Partners LP Common Units Representing Limited Partner Interests

USA Compression Partners LP provides compression services in the United States in terms of total compression fleet horsepower to customers relating to infrastructure applications, including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. It engineers, designs, operates, services, and repairs its compression units and maintains related support inventory and equipment. The company provides compression services in several shale plays throughout the U.S., including the Utica, Marcellus, Permian, Denver-Julesburg, Eagle Ford, Mississippi Lime, Granite Wash, Woodford, Barnett, and Haynesville.

Share on Social Networks: